Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a dipalmitoylated derivative of the anticancer drug FUdR as a prodrug in their bilayers. We investigated the in vitro interaction of these liposomes with CC531 target cells and the mechanism by which they deliver the active drug FUdR intracellularly to the cells by monitoring the fate of the liposomal bilayer markers cholesterol-[(14)C]oleate and [(3)H]cholesteryloleylether as well as the (3)H-labeled prodrug and colloidal gold as an encapsulated liposome marker. After binding of the immunoliposomes to the cell surface, only limited amounts were internalized as demonstrated by a low level of hydrolysis of liposomal cholesterol ester and by morphological studies employing colloidal gold-labeled immunoliposomes. By contrast, already within 24 h immunoliposome-incorporated FUdR-dP was hydrolyzed virtually completely to the parent drug FUdR intracellularly. This process was inhibited by a variety of endocytosis inhibitors, indicating that the prodrug enters and is processed by the cells by a mechanism involving an endocytic process, resulting in intracellular FUdR concentrations up to 3000-fold higher than those in the medium. Immunoliposomes containing poly(ethyleneglycol) (PEG) chains on their surface, with the antibody coupled either directly to the bilayer or at the distal end of the PEG chains were able to deliver the prodrug into the tumor cells at the same rate as immunoliposomes without PEG. Based on these observations, we tentatively conclude that during the interaction of the immunoliposomes with the tumor cells the lipophilic prodrug FUdR-dP is selectively transferred to the cell surface and subsequently internalized by constitutive endocytic or pinocytic invaginations of the plasma membrane, thus ultimately delivering the prodrug to a lysosomal compartment where hydrolysis and release of parent drug takes place. This concept allows for an efficient delivery of a liposome-associated drug without the need for the liposome as such to be internalized by the cells.
Koning
G A
GA
Department of Physiological Chemistry, Groningen University Institute for Drug Exploration (GUIDE), Faculty of Medical Sciences, University of Groningen, A. Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
Morselt
H W
HW
Velinova
M J
MJ
Donga
J
J
Gorter
A
A
Allen
T M
TM
Zalipsky
S
S
Kamps
J A
JA
Scherphof
G L
GL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D004337:Drug Carriers; D004705:Endocytosis; D005467:Floxuridine / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000031:analogs & derivatives; D008081:Liposomes; D008854:Microscopy, Electron; D010168:Palmitates / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011355:Prodrugs / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D051381:Rats; D014407:Tumor Cells, Cultured
C121179:5-fluorodeoxyuridine-dipalmitate; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D010168:Palmitates; D011355:Prodrugs; D005467:Floxuridine; D011092:Polyethylene Glycols